Ivosidenib and azacitidine Ivosidenib is a targeted cancer drug. It is also known as Tibsovo. Azacitidine is a chemotherapy drug. It is also called Vidaza. You pronounce ivosidenib as ...

Ivosidenib is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic ...

Ivosidenib plus azacitidine is recommended, within its marketing authorisation, as an option for untreated acute myeloid leukaemia (AML) with an IDH1 R132 mutation in adults who cannot have standard ...

The ivosidenib group had longer OS rates at 12 months (62.9% vs. 38.3%) and 24 months (53.1% vs. 17.4%). Researchers observed steady increases in hemoglobin levels from baseline until they ...

Servier today announced updates to two of its Phase 3 programs evaluating TIBSOVO (ivosidenib tablets) in isocitrate dehydrogenase 1 (IDH1)-mutated cancers. The first patient has been enrolled in ...

Research Summary Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia April 20, 2022 DOI: 10.1056/NEJMdo006476 Save ...

Background: Ivosidenib (IVO) twas approved based on a CR/CRh rate of 31.8% in IDH1 mutant (IDH1m) R/R AML; median duration of CR/CRh (DOR) was 8.2 months (mo). The purpose of this study is to ...

The Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) for the treatment of adults with previously treated locally advanced or metastatic IDH1-mutated cholangiocarcinoma (CCA), a ...

The FDA approved ivosidenib for treatment of certain adults with relapsed or refractory myelodysplastic syndromes.The indication applies to use of the agent in adults who harbor susceptible ...

ClarIDHy Phase 3 Trial The ClarIDHy trial is a global, randomized Phase 3 trial in previously treated IDH1-mutant cholangiocarcinoma patients who have documented disease progression following one ...

Ivosidenib (Tibsovo) Ivosidenib is a type of targeted cancer drug. It is also known as Tibsovo. You pronounce it as i-voh-sih-deh-nib. You might have ivosidenib if the cancer has a change (mutation) ...